Nordic ListingsIssuer Report
Promimic AB: Quarterly Trading Report 2025 Q3
Promimic AB: Quarterly Trading Report 2025 Q3https://view.news.eu.nasdaq.com/view?id=be77d8c0fe6db21aec1ec851d19816308&lang=en&src=omxlink
Promimic AB: Quarterly Trading Report 2025 Q3
Watch Promimic's latest callPromimic (Stockholm:PRO) Q3 2025 Earnings Call · Replay · Nov 19, 2025Read the transcript of Promimic (Stockholm:PRO) Q3 2025 Earnings CallEarlier from Promimic
- PRO: Record new agreements, positive EBITDA, and updated growth targets despite market headwinds
- PRO: Q1 2025 saw sales growth, new strategic deals, and improved cash flow despite a net loss
- PRO: Record sales and clinical milestones achieved, with robust growth outlook for 2025
- PRO: Sales up 6% in Q3, with record product approvals and strong royalty growth
- PRO: Record sales and robust growth, with new clinical approvals fueling future expansion
Later from Promimic
- Promimic Q3 Sales Of SEK 12.9 Mln
- PRO: Record new customer agreements and US expansion underpin double-digit adjusted growth
- Promimic Nomination Committee Proposes New Chairman
- Promimic Q1 2026 Operating Loss At SEK 3.5 Mln
Follow Promimic into a list and get an email when it puts out news.
Follow Promimic